Programmdetails

Freie Vortragssitzungen

Kardio-onkologische Aspekte bei Kardiovaskulären Erkrankungen

Mittwoch, 23. April | 13:30 - 15:00 Uhr | Clinical Case Corner

Vorsitz/Chair: Ziya Kaya (Heidelberg), Stefanie Keymel (Solingen)

Agenda

13:30
(V92)
High incidence of immune checkpoint inhibitor therapy related subclinical cardiac dysfunction and myocarditis in patients with extracardiac immune related adverse events
R. Mincu (Essen)
Zum Abstract
13:37
Diskussion
13:41
(V93)
Risk stratification for cardiac events based on high sensitive cardiac troponin T (hs-cTnT) for cardio-oncologic patients
M. Dörr (Heidelberg)
Zum Abstract
13:48
Diskussion
13:52
(V94)
Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy – a real-world observational study
T. Lerchner (Essen)
Zum Abstract
13:59
Diskussion
14:03
(V95)
Safety of SGLT2-Inhibitors in cardio-oncology patients with heart failure undergoing cancer treatment
V. Kokabi (Wien)
Zum Abstract
14:10
Diskussion
14:14
(V96)
Safety and feasibility of high intensity interval training (HIIT) during cardiotoxic cancer treatment - ENTRANCE - a pilot study
K. Seuthe (Köln)
Zum Abstract
14:21
Diskussion
14:25
(V97)
Impact of Cancer in Patients Undergoing Mitral Transcatheter Edge-To-Edge Repair: A Singe-Center Study
J. Soldat (Essen)
Zum Abstract
14:32
Diskussion
14:36
(V98)
Impact of an exercise programme on cardiac changes in cancer therapy-related cardiac dysfunction (CTRCD): Protocol for a single-centre, randomised controlled trial
J. Schellenberg (Ulm)
Zum Abstract
14:43
Diskussion
14:47
(V99)
Immune checkpoint inhibitor therapy: Heart complaints, myocarditis, cardiovascular mortality? Insights from real-world melanoma patients treated at a German university hospital.
H. Kocaman (Tübingen)
Zum Abstract
14:54
Diskussion
Diese Seite teilen